CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 5,373	$ (2,448)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	4,965	5,161
Share based compensation	(7,179)	5,196
Deferred income taxes	(231)	(436)
Bad debt expense	324	53
(Increase) decrease in operating assets and increase (decrease) in operating liabilities:
Accounts receivable	700	(119)
Inventories, net	16,761	(12,438)
Prepaid income taxes	(152)	65
Prepaid expenses and other current assets	2,437	(2,664)
Operating lease right-of-use assets, net	355	594
Accounts payable	(26,078)	7,929
Sales tax payable	(529)	(1,942)
Accrued expenses and other current liabilities	2,756	(1,258)
Lease liabilities	(349)	(577)
Deferred revenue	(1,447)	75
Net cash used in operating activities	(2,294)	(2,808)
Cash flows from investing activities:
Purchase of minority interest investment in Vetster	0	(300)
Acquisition of PetCareRx, net of cash acquired	0	(35,859)
Purchases of property and equipment	(2,725)	(3,260)
Net cash used in investing activities	(2,725)	(39,419)
Cash flows from financing activities:
Dividends paid	(176)	(12,419)
Net cash used in financing activities	(176)	(12,419)
Net decrease in cash and cash equivalents	(5,195)	(54,646)
Cash and cash equivalents, at beginning of period	55,296	104,086
Cash and cash equivalents, at end of period	50,101	49,440
Supplemental disclosure of cash flow information:
Cash paid for income taxes	474	43
Dividends payable in accrued expenses and other current liabilities	32	1,498
Non-cash investing activity for PPE additions	$ 2,539	$ 0